May 6, 2021
Hospira recalls one lot each of 0.5% Bupivacaine and 1% Lidocaine because of mislabeling
Editor's Note
Hospira Inc, a Pfizer company, announced May 4 that it is recalling lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection, USP 30 mL and lot EG8933 of 1% Lidocaine HCL Injection, USP 30 mL because of mislabeling.
A portion of each lot was incorrectly labeled as the other product. The issue was identified by a customer.
Use of the impacted products could cause adverse events of moderate to high severity.
Free Daily News
- Contribute to perioperative education with the 2024 OR Manager Salary/Career Survey
- Supply chain stability improves, but threats remain
- Private equity healthcare ownership draws new scrutiny
- Share your expertise! Topics, speakers sought for 2025 ORBMC
- FDA approves imaging drug for detecting cancer after lumpectomy
- Penn Medicine anesthesia, waste initiatives boost OR sustainability
- Survey assesses continued impact of Change Healthcare cyberattack
- WHO sounds alarm on potential spread of bird flu
- Allison Massari to deliver hopeful, empowering keynote address at OR Manager Conference 2024
- Neurosurgery trial: Early evacuation improves long-term hemorrhage outcomes
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging